Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases

Chiara Trevisiol, F. Di Fabio, R. Nascimbeni, L. Peloso, C. Salbe, E. Ferruzzi, B. Salerni, M. Gion

Research output: Contribution to journalArticlepeer-review


While tissue KRAS2 mutations have been extensively investigated, the role of circulating mutant KRAS2 gene in patients with colorectal carcinoma remains obscure. The aim of the present study was to explore the prognostic significance of circulating KRAS2 gene mutational status in subjects undergoing primary treatment for colorectal cancer. Codon 12 KRAS2 mutations were examined in DNA samples extracted from the serum of 86 patients with colorectal cancer and were compared with the KRAS2 status of their primary tumors. Tissue and serum KRAS2 status was compared with other clinicopathological variables (including CEA and CA 19-9 levels) and with cancer-related survival. KRAS2 mutations were found in tissue samples of 28 patients (33%); serum KRAS2 mutations were detected in 10 of them (36%). Serum KRAS2 status was significantly associated with Dukes' stage D (p=0.001) and with preoperative CA 19-9 levels (p=0.01). At multivariate analysis, cancer-related survival was associated with Dukes' stage (p

Original languageEnglish
Pages (from-to)223-228
Number of pages6
JournalInternational Journal of Biological Markers
Issue number4
Publication statusPublished - Oct 2006


  • Biological markers
  • Colorectal neoplasms
  • Genes
  • Prognosis
  • Ras
  • Serum

ASJC Scopus subject areas

  • Immunology
  • Biochemistry


Dive into the research topics of 'Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases'. Together they form a unique fingerprint.

Cite this